MMOOZZGG.com

Fields

AI cancer screening: find cancer earlier and miss less

2 min read8 sources

AI cancer screening now has randomized trial evidence: breast screening, colonoscopy, finding pancreatic cancer on routine CT, and risk assessment by a general practitioner. Below are the numbers you can check through the links, and what they mean for clinics.

On this page · 3 sections

Breast screening

A Swedish trial of 106,000 women: 29% more cancers found, 44% less radiologist workload, 12% fewer interval cancers, and among them 27% fewer aggressive subtypes (The Lancet, January 2026). Scotland: 12% more cancers among 10,889 women, and in a workflow model the workload fell by up to 30% (2024). The United Kingdom started a trial with nearly 70,000 women at 30 sites and 11 million pounds of funding (2025). In Russia, AI mammography is among the studies paid for by compulsory health insurance; in the Krasnodar Territory, a case is described of an aggressive tumor that AI found after a clean first reading.

Other cancer sites

Pancreatic cancer: a model on routine CT without contrast found 31 cases among more than 20,000 patients where radiologists saw nothing, with one false alarm per 1,000 (Nature Medicine, 2023). Colonoscopy: a Russian randomized trial with 1,128 patients raised adenoma detection from 41.3% to 47.2%, and after midday the effect grew to 9.2 points. Primary care: a risk platform in 1,084 practices in England, according to the developer, raised the share of confirmed cancers by 20% against the national average and avoided more than 61,000 unneeded urgent referrals.

What this means for clinics

The effect of AI in cancer care is measured by three numbers: extra cases found, unneeded referrals and doctor time saved. Rollout goes through registered medical devices and a second reading by a doctor. The service side of cancer care, such as booking, reminders for follow-up exams and documents, can be automated without registration.

Questions and answers

Is there a risk that AI finds too much?

Yes, and that is why trials count false positives. In the Swedish trial their number did not rise, and in the Stockholm hospital it fell.

Sources and fact-checking

Checked by the editors on 29 September 2026.

  1. Lund University, 30 January 2026: Lund University, Sweden (lunduniversity.lu.se)
  2. Alizila, Alibaba Group, 6 December 2023: DAMO Academy, China (alizila.com)
  3. University of Aberdeen, 21 March 2024: NHS Grampian and the University of Aberdeen, Scotland (abdn.ac.uk)
  4. Lunit, 2 December 2024: Capio S:t Göran Hospital, Stockholm (lunit.io)
  5. PR Newswire, C the Signs, 28 April 2025: 1,084 NHS general practices, England (prnewswire.co.uk)
  6. Clinical Trials Arena, 4 February 2025: NHS and NIHR, United Kingdom (clinicaltrialsarena.com)
  7. Digital Platforms, case no. 2779, 2024: Ryzhikh National Medical Research Center of Coloproctology (platforms.su)
  8. Digital Platforms, case no. 2782: Ministry of Health of the Krasnodar Territory (platforms.su)

Found a mistake? Tell us

Publications

Mike Mozg

Agentic AI use cases at AT&T: nearly 500 processes now run on agents

AT&T no longer uses AI only to help staff work faster: it is rebuilding whole business processes around agents. SiliconANGLE reported on 14 November 2026 that nearly 500 agentic AI use cases at AT&T are already in production. Here is how the company rebuilds them, where a human still checks the agent, and what other large companies can take from it.

News4 min

Cases on this topic: 7

  • Market case · World

    Lund University, Sweden 29% more breast cancers found and 44% less radiologist workload, 106,000 women

    The randomized MASAI trial of 106,000 women showed that AI mammography screening finds 29% more cancers with no rise in false positives, and the workload of radiologists falls by 44%. The final results appeared in The Lancet in January 2026.

    Oncology

    30 January 2026 · source: lunduniversity.lu.se

    Read the case
  • Market case · World

    DAMO Academy, China 5 cancers and 26 other pancreatic lesions missed at the first diagnosis were found among 20,530 patients

    The model for AI pancreatic cancer detection on an ordinary CT scan without contrast was tested on 6,239 patients from 10 centers. Its sensitivity in finding cancer was 34.1% higher than the average radiologist. In a retrospective test on 20,530 patients in a row, the AI found 5 cancers and 26 other lesions missed at the first diagnosis, with 99.9% specificity: about one false alarm per 1,000 studies.

    Oncology

    20 November 2023 · source: nature.com

    Read the case
  • Market case · World

    NHS Grampian and the University of Aberdeen, Scotland +12% breast cancers found in 10,889 women, up to 30% less workload by estimate

    The first formal prospective evaluation of this AI tool in UK breast screening: in a study of 10,889 women, AI breast cancer screening helped find 12% more cancers than usual practice, mostly invasive and high grade. Modeling showed up to 30% less workload for radiologists.

    Oncology

    21 March 2024 · source: abdn.ac.uk

    Read the case
  • Market case · World

    Capio S:t Göran Hospital, Stockholm +15% cancers detected, -11% recalls, image reading 36% faster

    A Stockholm hospital replaced one of the two radiologists who read each image in its screening program with AI. According to the developer, after the rollout cancer detection rose from 4.8 to 5.5 per 1,000 women examined, the recall rate fell from 2.8% to 2.5%, and reading time became more than 36% shorter.

    Oncology

    2 December 2024 · source: lunit.io

    Read the case
  • Market case · World

    1,084 NHS general practices, England 20% more confirmed cancers and over 61,000 urgent referrals avoided

    The developer reports that GPs in 1,084 practices used its cancer risk assessment platform: more than 235,000 risk assessments and 13,585 cancers diagnosed between January 2020 and September 2024. The share of referrals that ended in a diagnosis was 20% above the national average, and more than 61,000 unnecessary urgent referrals were avoided.

    Oncology

    28 April 2025 · source: prnewswire.co.uk

    Read the case
  • Market case · World

    NHS and NIHR, United Kingdom almost 70,000 women and 30 sites in an announced £11 million AI screening trial

    On 4 February 2025, the UK government announced the EDITH trial of AI breast screening. Almost 70,000 women at 30 sites are to take part, with £11 million of funding from the National Institute for Health and Care Research. The goal: to test whether screening mammography can use one specialist instead of two.

    Oncology

    4 February 2025 · source: clinicaltrialsarena.com

    Read the case
  • Market case · Russia

    Ryzhikh National Medical Research Centre of Coloproctology adenoma detection rate of 47.2% against 41.3% in a randomized trial of 1,128 patients

    The first Russian decision support system for colonoscopy highlights subtle polyps on the screen in real time. A multicenter randomized trial in 4 clinics with 1,128 patients showed an adenoma detection rate of 47.2% with AI against 41.3% without AI.

    Endoscopy

    2024 · source: platforms.su

    Read the case
All cases: 62
Contact us